Abstract-Recent evidence suggests that apoptosis may be involved in the control of vascular smooth muscle cell (VSMC) number in atherosclerotic lesions. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been reported to induce apoptosis in a variety of tumor cell lines. To evaluate whether these agents also induce apoptosis of VSMCs, cultured rat VSMCs were treated with increasing doses of atorvastatin in the presence of FBS as a survival factor. The presence of apoptosis was evaluated by morphological criteria, annexin V binding, and DNA fragmentation and quantified as the proportion of hypodiploid cells by flow cytometry. Atorvastatin induced apoptosis in a dose-dependent manner, an effect also seen with simvastatin and lovastatin, but not with the hydrophilic drug pravastatin. The proapoptotic effect of statins was seen only when the inhibition of acetate incorporation into sterols was Ͼ95% and was fully reversed by mevalonate, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate but not by isopentenyl adenosine, ubiquinone, or squalene, suggesting a role for prenylated proteins in the regulation of VSMC apoptosis. To further assess the role of protein prenylation, VSMCs were exposed to the prenyl transferase inhibitors perillic acid and manumycin A. Both agents induced VSMC apoptosis as evaluated by the above-mentioned criteria. Finally, VSMC treatment with lipophilic statins was associated with decreased prenylation of p21-Rho B, further supporting the role of protein prenylation inhibition in statin-induced VSMC apoptosis. The present data suggest that interference with protein prenylation by HMG-CoA reductase inhibitors or other agents may provide new strategies for the prevention of neointimal thickening. (Circ Res. 1998;83:490-500.)
A poptosis has recently been reported to be present in human atherosclerosis and in experimental models of vascular damage and virtually absent in normal vessels, suggesting a potential role for apoptosis in the pathophysiology of vascular injury. [1] [2] [3] [4] [5] [6] Human vascular smooth muscle cells (VSMCs) from atheromatous lesions are more likely to undergo apoptosis than are VSMCs derived from normal arteries. 7 In addition, apoptosis is more frequent in proliferative lesions, particularly restenosis lesions. 3, 5 The temporal sequence of proliferation and apoptosis in experimental models is consistent with a role for apoptosis in the control of neointimal cellularity. 1 Accordingly, VSMC apoptosis has been proposed to play a significant role in the control of neointimal thickening. 5, 6, 8 In spite of its potential importance, little is known regarding the mechanisms controlling VSMC apoptosis in vivo.
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins, Figure 1 ) have been shown to be efficacious in reducing cardiovascular morbidity and mortality in primary and secondary prevention clinical trials. 9 -11 Although the salutary effects of these agents may be explained by their beneficial actions on the lipid profile, increasing evidence suggests that statins may also exhibit effects unrelated to lipid reduction ( Figure 1) . [12] [13] [14] In experimental models, HMG-CoA reductase inhibitors reduced neointimal thickening regardless of the effect of cholesterol. [15] [16] [17] [18] Neointimal VSMC number is the result of the migration of VSMCs from the media and their subsequent proliferation and eventual death, including programmed cell death. 19, 20 Much of the attention on the effects of statins on VSMC biology has been devoted to migration and proliferation. 16, [21] [22] [23] [24] [25] Indeed, both phenomena can be attenuated by HMG-CoA reductase inhibition and have been proposed as potential mechanisms of action in the prevention of vascular damage by statins. HMG-CoA reductase inhibitors induce programmed cell death in a variety of cell lines. 26 -30 In spite of its potential relevance, no attempts to evaluate the effect of HMG-CoA reductase inhibitors on VSMC apoptosis have been reported. In the present study, we show that lipophilic HMG-CoA reductase inhibitors induce apoptosis of VSMCs even in the presence of survival factors. This effect is paralleled by an attenuation of the prenylation of p21-Rho B and is reversed by the addition of mevalonate, farnesyl pyrophosphate (F-PP), and/or geranylgeranyl pyrophosphate (GG-PP), suggesting a role for isoprenylated proteins such as Rho B in the apoptosis of VSMCs induced by statins. Our data suggest that interference with protein prenylation by HMG-CoA reductase inhibitors or other agents may provide new strategies for the prevention of neointimal thickening.
Materials and Methods

Reagents and Chemicals
DMEM, penicillin, streptomycin, and trypsin-EDTA were from Bio Whitaker. FBS was from GIBCO. Atorvastatin (sodium salt, dissolved in Tris borate, pH 8) was obtained from Parke Davis. Lovastatin and simvastatin (from Merck Sharp and Dohme Spain) were converted to the active compounds as described by Kita et al. 31 Pravastatin was obtained from Bristol Myers-Squibb Spain and dissolved in NaCl (155 mmol/L). Perillic acid and manumycin A (from Sigma Chemical Co) were dissolved in ethanol and DMSO, respectively. FITC annexin V was kindly provided by Dr J. Turnay (School of Chemistry, Universidad Complutense, Madrid, Spain). [ 3 H]Acetic acid (sodium salt; specific activity, 2.52 Ci/mmol) was from DuPont NEN. Rabbit anti-Rho B polyclonal antibody (Sc-180) was from Santa Cruz Biotechnology. The remaining reagents were obtained from Sigma unless specified otherwise.
VSMC Culture
Rat thoracic aorta smooth muscle cells were isolated essentially as described by Owens et al. 32 Briefly, male Sprague-Dawley rats weighing 200 to 250 g were killed by an overdose of pentobarbital, and the thoracic aorta was aseptically excised and placed in PBS. Adhering fat and connective tissue were removed by blunt dissection. The aorta was opened longitudinally and preincubated in DMEM containing collagenase (type II, 290 U/mL), penicillin (100 U/mL), and streptomycin (100 g/mL) for 15 to 20 minutes at 37°C in 95% air/5% CO 2 . After dissection, aortas were placed in fresh enzyme solution, minced into 1-mm pieces, and incubated for an additional 1.5 to 2 hours. Pieces were rinsed twice with PBS to remove the cells, and PBS was then centrifuged. The cells were resuspended in DMEM with antibiotics and 10% FBS, counted, and seeded at a concentration of 10 4 cells/cm 2 in plastic culture flasks (Costar). Cells were characterized as smooth muscle cells by their typical hill-and-valley morphology by phase-contrast microscopy and by positive immunostaining for ␣-smooth muscle actin (clone 1A4, Sigma). Media were replaced every 2 to 3 days. At confluence, cells were harvested for passaging with trypsin-EDTA. Cells between passages 3 and 12 were used for all the experiments.
Cell DNA Staining
Adherent cells were washed once with PBS and incubated with PBS containing 9.4 mol/L bisbenzimide (Hoechst 33342) for 20 minutes in the dark and examined under fluorescence microscopy. Floating cells were collected by centrifugation, and a cell smear was stained with bisbenzimide as indicated above.
Flow Cytometry Assessment of Cell Death
Cellular DNA content was assessed by flow cytometry. For this purpose, cells were cultured in 12-well plates and treated as appropriate. Cells attached to the plate were collected with trypsin and 2.2 mmol/L EDTA in PBS and mixed with detached cells present in the supernatant. Cells were spun and resuspended in a solution containing 75 mol/L propidium iodide, 10 mg/L RNase A, and 0.05% Nonidet P-40 in PBS; then they were incubated at 4°C for 30 minutes in the dark and analyzed by flow cytometry (Coulter EPICS XL-MCL flow cytometer, Hialeah, FL) using LYSIS II software. 33, 34 The percentage of cells with decreased DNA staining (A 0 ), composed of apoptotic cells resulting from either fragmentation or decreased chromatin, of a minimum of 5000 to 10 000 cells per experimental condition was counted. Cell debris were excluded from analysis by selective gating based on anterior and right angle scatter. As assessed by flow cytometry, none of the solvents of the different compounds, up to the highest dose used in our experimental conditions, induced any significant degree of apoptosis.
DNA Electrophoresis
For the evaluation of DNA fragmentation, 10 million cells were incubated under the different experimental conditions for 48 hours and assayed essentially as described. 35 At the end of this period, floating and adherent cells were collected, rinsed twice with cold PBS, and lysed by incubation in 20 mmol/L EDTA, 50 mmol/L Tris-HCl (pH 8), and 0.5% (wt/vol) sodium lauroylsarcosine for 30 minutes at 4°C. Cell debris and high-molecular-weight DNA were precipitated by centrifugation at 12 000g for 30 minutes at 4°C. Supernatants containing fragmented DNA were then treated with proteinase K (0.2 g/L) at 50°C for 1 hour and 2 g/L RNase A at 50°C for another hour and run in a 1.5% agarose gel containing ethidium bromide. Gels were examined and photographed under UV light.
Flow Cytometry Assessment of Annexin V Binding
Annexin V binding was studied essentially as described by Vermes et al, 36 37 The chloroform fractions were dried under N 2 , resuspended in 2 mL of 1 mol/L KOH in 95% ethanol, and saponified at 90°C for 50 minutes. Nonsaponifiable lipids were extracted twice with 1.2 mL of hexane and dried under N 2 . Four hundred micrograms of cholesterol and 2 mL of isopropanol were added to each sample. Sterols were then precipitated by the addition of 1 mL of digitonin reagent (1% digitonin in 50% ethanol) and incubation at 4°C for 30 minutes. 38 Samples were spun, and the precipitate was washed twice with cold acetone and resuspended in 2 mL of methanol. Precipitates were extensively resuspended with 2 additional washes with methanol, pooled, and dried before counting in scintillation vials.
Immunoblotting
Cells from different experimental conditions were collected, rinsed twice with cold PBS, and pelleted. Cells were then briefly sonicated in 1 mL of PBS containing 2 mmol/L EDTA, 2 mmol/L phenylmethylsulfonyl fluoride, and 1 mol/L pepstatin A. Cell membranes were collected by centrifugation at 50 000g for 30 minutes and resuspended in 100 mmol/L Tris-HCl, 300 mmol/L NaCl, 1% Triton X-100, and 0.1% SDS containing 2 mmol/L EDTA, 2 mmol/L phenylmethylsulfonyl fluoride, and 1 mol/L pepstatin A. Protein in membrane or soluble extracts was calculated by the BCA method (Pierce). Equal amounts of protein (50 to 100 g) were loaded into 12% acrylamide gels and electrophoresed as described. 39 The resolved proteins were transferred onto PVDF membranes (Immobilon, Millipore). The nonspecific sites of the membrane were blocked by incubation at room temperature 1 hour in 7.5% nonfat dry milk powder in PBS containing 0.1% Tween 20 (PBST). The membrane was incubated overnight at 4°C with rabbit anti-Rho B polyclonal antibody (Sc-180, Santa Cruz Biotechnology) in PBST containing 5% nonfat dry milk. The membrane was washed with PBST and incubated 1 hour at room temperature with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology) in PBST containing 5% nonfat dry milk. The membrane was then washed with PBST and incubated 30 minutes in PBST containing 400 mmol/L NaCl, followed by detection with enhanced chemiluminescence (ECL kit, Amersham). Films were scanned on a densitometer and quantified using ImageQant software (Molecular Dynamics).
Data Presentation
Representative data from 2 to 5 independent experiments are presented. For quantitative data, the meanϮSD of triplicate or quadruplicate samples from 1 of 3 to 5 independent experiments is presented. For the comparison of group means, 1-way ANOVA and Student-Newman-Keuls tests were used as appropriate. A value PϽ0.05 was considered statistically significant. 
Results
Atorvastatin and Lipophilic HMG-CoA Reductase Inhibitors Induce Apoptosis of VSMCs
To evaluate whether HMG-CoA reductase inhibitors induce apoptosis of VSMCs, exponentially growing subconfluent rat VSMCs were exposed to increasing concentrations of the HMG-CoA reductase inhibitor atorvastatin for 24 hours in the presence of 10% FBS as a survival factor. Atorvastatin treatment was associated with cell rounding and detachment from the plate substrate and surrounding cells, as assessed by inverted phase microscopy, in a dose-dependent manner ( Figure 2 ). Staining with DNA-binding dyes revealed that treatment of VSMCs with atorvastatin was associated with the appearance of chromatin condensation and fragmentation characteristic of apoptosis ( Figure 2 ). These changes were particularly prominent in detached cells floating in the culture media. To further confirm that atorvastatin induced apoptosis of VSMCs, the cell DNA content was assessed by flow cytometry. Atorvastatin treatment was associated with the appearance of a cell population with a reduced DNA content (hypodiploid), usually referred to as sub G 1 or A 0 , characteristic of apoptosis (Figures 3 to 5) . Most dramatic reductions of DNA content were evident in floating cells (not shown), mirroring the effects on chromatin fragmentation. The reduction in cellular DNA content was paralleled by the appearance of DNA fragmentation into multiples of 180 to 200 kb, constituting a typical laddering pattern characteristic of apoptosis ( Figure 6 ). Finally, atorvastatin treatment was also associated with increased binding of annexin V, a recently described early indicator of apoptosis ( Figure 7) . 36 Again, most of the increased annexin V binding was attributable to floating cells. Mevalonate, in a dose-dependent manner, completely reversed the effects of atorvastatin in cell morphology, DNA content, and fragmentation, and annexin V binding ( Figures 2 to 4, 6 , and 7), suggesting that the effects of atorvastatin were indeed related to the inhibition of the mevalonate pathway. To ascertain whether the effects of atorvastatin were shared by other HMG-CoA reductase inhibitors, VSMCs were incubated with increasing concentrations of 2 lipophilic (simvastatin and lovastatin) and 1 hydrophilic (pravastatin) HMG-CoA reductase inhibitor. Both simvastatin and lovastatin produced changes similar to those observed with atorvastatin with an even higher potency, whereas pravastatin (up to 100 mol/L) failed to induce any of the above-mentioned effects (Figures 4 and 6) . In every case, the addition of mevalonate completely reversed the statin-induced effects (Figures 4 and 6) .
We further assessed whether the above-described effects were indeed related to the degree of inhibition of the mevalonate pathway. First, the antiapoptotic effect of mevalonate was specific for statins, since mevalonate failed to prevent VSMC apoptosis induced by other agents, such as pyrrolidinedithiocarbamate or manumycin A (not shown). Second, the proapoptotic effect of statins was very closely related to the degree of inhibition of the mevalonate pathway, as assessed by the inhibition of the incorporation of [ 3 H]acetate into sterols. Indeed, apoptosis was present only when the inhibition of sterol synthesis was Ͼ95% (Figure 4 , bottom). All the above data strongly suggest that the depletion of some mevalonate metabolite(s) is involved in the statin-induced apoptosis of VSMCs.
Mevalonate Metabolites and Apoptosis of VSMCs
To evaluate which among mevalonate metabolites may be important in atorvastatin-induced apoptosis, the reversal of atorvastatin effects by several mevalonate derivatives ( Figure  1 ) was assessed next. Neither cholesterol (present in the serum-supplemented media) nor its precursor, squalene (1 to 25 mol/L), prevented atorvastatin-induced apoptosis (not shown), suggesting that sterols do not play a prominent role in our experimental conditions. Similarly, neither isopentenyl adenosine (1 to 25 mol/L) nor ubiquinone (coenzyme Q10, 1 to 25 mol/L) reversed the atorvastatin-induced apoptosis of VSMCs (not shown). In contrast, both F-PP and GG-PP reversed, in a dose-dependent manner, the atorvastatin effects in cell morphology, DNA content and fragmentation, and annexin V binding (Figures 5 to 7) .
Isoprenylation Inhibition and Apoptosis of VSMCs
Since both F-PP and GG-PP are used for the posttranslational modification of several cell proteins, we next evaluated the effects of 2 inhibitors of protein prenylation: perillic acid and manumycin A. In atorvastatin-treated mevalonate-repleted cells, the weak inhibitor of prenylation perillic acid induced, in a dose dependent manner, the appearance of the morphological changes, annexin V binding, DNA content reduction, and laddering characteristic of apoptosis in a significant, albeit small, proportion of VSMCs (Figures 2, 7, and 8 ). In agreement with its higher inhibitory potency, manumycin A induced, in a dose-dependent manner, apoptosis in a higher proportion of VSMCs (Figures 2, 7, and 8 ). As expected, the addition of exogenous mevalonate (100 mol/L) did not modify the manumycin-induced effects (not shown). Another farnesyl transferase inhibitor, ␣-hydroxyfarnesyl phosphonic acid, also induced in a dose-dependent manner the appearance of VSMC apoptosis (not shown). 3 H]acetate into sterols was measured, as described in Materials and Methods (controlϭ100%). Values are representative of 2 independent experiments. *PϽ0.05 vs control. Atorvastatin, lovastatin, and simvastatin treatment induced, in a dose-dependent manner, the appearance of an increased proportion of cells with hypoploid DNA content (A 0 , arrow), characteristic of apoptosis. These effects were fully reversed by mevalonate. In contrast, pravastatin treatment did not increase the proportion of cells with reduced DNA content. Changes consistent with apoptosis were observed only when sterol synthesis was inhibited by Ͼ95%.
HMG-CoA Reductase Inhibition and Protein Prenylation
The above-presented data suggest that inhibition of protein prenylation may be important in VSMC apoptosis. Therefore, we evaluated whether HMG-CoA reductase treatment was in fact associated with changes in the level of prenylation of the protein p21-Rho B, a protein that has been found to play an important role in apoptosis. Under normal conditions p21-Rho is anchored into the cell membrane by its covalent binding to either farnesyl or geranylgeranyl. When protein prenylation is inhibited, Rho B remains in the cytoplasm. The evaluation of the degree of presence of Rho B in the membrane or cytoplasmic compartments of the cells is therefore an indirect assessment of its degree of prenylation. As shown in Figure 9 , treatment of VSMCs with lipophilic statins, but not pravastatin, was associated with an attenuation of the presence of Rho B in the membrane and its appearance in the cytoplasmic fraction. Interestingly, the degree of inhibition of Rho B prenylation (as assessed by its compartmentalization) by different statins closely parallels the proapoptotic effect of statins. Again, treatment with mevalonate, F-PP, or GG-PP was associated with the disappearance of Rho from the cytoplasm and its restoration into the membrane fraction.
Discussion
The present data show that HMG-CoA reductase inhibition by atorvastatin induces changes of cultured rat VSMCs characteristic of apoptosis: cell rounding, detachment from the culture substrata and adjacent cells, chromatin condensation and fragmentation, increased annexin V binding, reduction of cellular DNA content, and internucleosomal fragmentation. 36, 40 The effects are specific to the inhibition of the mevalonate pathway, since the addition of exogenous mevalonate completely reversed the atorvastatin-induced effects. Conversely, the antiapoptotic effect of mevalonate is restricted to statins: it is ineffective in reversing apoptosis induced by other agents, such as pyrrolidinedithiocarbamate or manumycin. These proapoptotic effects are not restricted to atorvastatin, as 2 other agents of the same family, namely, simvastatin and lovastatin, produced similar qualitative effects. In contrast, the hydrophilic drug pravastatin failed to induce any significant changes when used in equimolar amounts. Not surprisingly, the proapoptotic effects of statins were tightly correlated with the degree of inhibition of the mevalonate pathway (Figure 4 ). Our results are quite similar to those reported regarding the effects of different statins on VSMC proliferation. 25 It is conceivable that in both cases, the hydrophilic properties of pravastatin and the lack of a specific transporter in nonhepatic cells prevented an adequate access of the drug to the cytoplasm. 41 In this regard, pravastatin, compared with atorvastatin, lovastatin, and simvastatin, was also less efficacious in reducing vascular injury in 2 experimental models of atherosclerosis. 17, 18, 25 Whether the potential benefits of a direct action of lipophilic statins on the vascular wall may be overshadowed by an increased incidence of extrahepatic side effects is at present unknown.
HMG-CoA reductase inhibition results in the reduction of the cellular content of a variety of sterol and nonsterol mevalonate metabolites. 42, 43 Many of these metabolites play prominent roles in cell biology that could potentially be involved in the mechanisms of apoptosis. Our data suggest that a profound inhibition of the mevalonate pathway is required for the induction of apoptosis. Cholesterol was present in the media as a part of the FBS, at concentrations considered to be sufficient for basic cellular functions. 44 Therefore, cholesterol depletion, in agreement with previous reports in other cell lines, 26 -30 does not seem to account for the induction of apoptosis in our experimental conditions. In addition, squalene, the first mevalonate metabolite committed to sterol synthesis, failed to reverse the atorvastatin-induced apoptosis of VSMCs, suggesting that nonsterol metabolites, rather than steroids, may play a major role. Similarly, isopentenyl adenosine, the precursor of isopentenyl tRNA, failed to reverse the atorvastatin effects and, consequently, does not seem to play a prominent role in our experimental conditions. In contrast, both F-PP and GG-PP, at concentrations in the micromolar range, completely abolished atorvastatin-induced effects. GG-PP is the precursor of ubiquinone, an important natural antioxidant. Since redox processes appear to be involved in the pathophysiology of VSMC apoptosis, 45, 46 the inhibition of ubiquinone synthesis may be of relevance. However, the addition of ubiquinone did not reverse atorvastatin-induced VSMC apoptosis, suggesting that GG-PP is acting through a different mechanism. Indeed, GG-PP and F-PP are used for the posttranslational modification of several important cell proteins. 42, 43, 47, 48 The attachment of an isoprenoid residue to these proteins is necessary for Figure 6 . Effects of HMG-CoA reductase and isoprenylation inhibitors on DNA fragmentation. Reversal by isoprenoids. Exponentially growing rat VSMCs were exposed to atorvastatin (0 to 100 mol/L), other statins (100 mol/l), perillic acid (10 mmol/L, in the presence of 100 mol/L atorvastatinϩ100 mol/L mevalonate [MVA]), or manumycin A (50 mol/L), as indicated. Some cells were exposed to 100 mol/L MVA, 10 mol/L F-PP, or 10 mol/L GG-PP in addition to 100 mol/L atorvastatin, as indicated. Fragmented DNA was extracted, run in a 1.5% agarose gel, stained with ethidium bromide, and photographed under UV light as described in Materials and Methods. As shown, treatment with atorvastatin was associated, in a dosedependent manner, with the appearance of a 180-to 200-bp DNA fragmentation pattern, typical of apoptosis. This effect of atorvastatin was virtually abolished by either MVA, F-PP, or GG-PP. Similarly, treatment with lipophilic statins (but not pravastatin) or isoprenylation inhibitors was also associated with the appearance of a DNA laddering pattern. their anchorage to cell membranes and full functionality. Prenylated proteins and, more specifically, small GTPbinding proteins are key elements in signal transduction from membrane receptors involved in proliferation and survival of VSMCs, such as growth factors, endothelin, angiotensin II, and thrombin. 49 Increasing attention has been directed in recent years to the development of prenyl transferase inhibitors in an attempt to inhibit tumor cell proliferation.
48,50 -52 Surprisingly, there are no reports dealing with the potential effects of prenyl transferase inhibition on VSMC apoptosis. To assess whether protein prenylation may play a role in the control of VSMC apoptosis, VSMCs were exposed to 2 unrelated inhibitors of protein prenyl transferases: perillic acid and manumycin A. 53, 54 Perillic acid and other limonene-related compounds are weak inhibitors of the prenylation of low-molecular-weight proteins and, for this reason, are commonly used in vitro in the presence of inhibitors of mevalonate synthesis and exogenous mevalonate repletion. 53 Under these conditions, perillic acid induced apoptosis in a dose-dependent manner in a modest proportion of cells in our experimental conditions. The effects of perillic acid alone were somewhat weaker (not shown). In contrast, the farnesyl transferase inhibitor manumycin A induced changes in cell morphology, annexin V binding, and DNA content characteristic of apoptosis in a higher proportion of cells. Perillic acid inhibits the farnesylation and geranylgeranylation of low-molecular-weight proteins, whereas manumycin A is a selective inhibitor of protein farnesylation. Although prenylated proteins are modified specifically by either farnesyl or geranylgeranyl in normal conditions, 47, 48 little is known regarding potential modifications by a different isoprenoid when the naturally occurring reaction is interfered pharmacologically. Protein prenylation is catalyzed by 3 different enzymes that recognize both the isoprenoid and the acceptor protein: farnesyl transferase and geranylgeranyl transferases I and II. 48 However, the specificity of these enzymes for their substrates is not absolute. Indeed, K-ras is normally farnesylated but can be alternatively modified by geranylgeranyl in the absence of farnesyl. 55 Similarly, the low-molecular-weight protein Rho B can be either geranylgeranylated or farnesylated by geranylgeranyl transferase I. 48, 56 Thus, it appears that proteins usually modified by GG-PP may be prenylated by F-PP and vice versa given the appropriate circumstances. These phenomena may underlie the capacity of either F-PP or GG-PP to reverse atorvastatin effects. Nevertheless, the fact that manumycin A induces apoptosis at concentrations of Ͼ50% inhibitory concentration (IC 50 ) for farnesyl transferase but well under the IC 50 for geranylgeranyl transferase I suggests that farnesylated proteins may be of particular importance. 54 More specifically, the inhibition of the prenylation of Rho may be critical. Indeed, the inhibition of Rho prenylation has very recently been described to produce apoptosis in fibroblasts, 57 and the membrane restoration of Rho can overcome this effect. 58 In addition, mutant constitutively active Rho prevents T-cell apoptosis, 59 whereas Rho inactivation is associated with increased T-cell apoptosis. 60 Therefore, we examined the effect of statins on the degree of Rho B prenylation in our experimental conditions. The effects of different statins on Rho prenylation were remarkably similar to their effects on VSMC apoptosis. In addition, the reversal of the inhibition of Rho prenylation by mevalonate or its derivatives was also associated with the abrogation of the proapoptotic effect of statins. On the whole, our results strongly suggest that the interference of the prenylation of proteins, such as Rho, by HMG-CoA reductase inhibition plays a prominent role in statin-induced VSMC apoptosis. Although Rho is an excellent marker of the effect of statins on protein prenylation and is a likely candidate to be involved in statin-induced apoptosis, our data cannot exclude that some other prenylated proteins may play a similar or even greater role.
It is difficult to ascertain how the present data may be of relevance to the in vivo situation. However, it should be noted that the concentrations of statins used in these and other experimental settings to induce apoptosis are similar to those used to inhibit cell proliferation. 16, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] This is hardly surprising, as the mechanisms regulating cell proliferation are inextricably connected to the regulation of programmed cell death. 49, 61, 62 In this regard, the induction of apoptosis of VSMCs might play a concurrent role with the inhibition of cell proliferation in the prevention of neointimal thickening, as proposed in experimental models. 16, 17 In addition, HMGCoA reductase inhibitors were able to induce apoptosis of VSMCs even in the presence of the survival factor, ie, FBS. The effect of statins might be enhanced in circumstances in which a certain degree of apoptosis is already taking place, such as in atheromatous plaque formation. Even if statins may favor smooth muscle cell apoptosis in vivo, the potential clinical importance of this phenomenon is controversial. On the one hand, increased apoptosis may contribute to an attenuation of the neointimal thickening seen in early atherosclerosis. 20 On the other hand, enhanced apoptosis may contribute to increased plaque instability and hence favor the appearance of vascular events. 19 Given all these considerations, the potential role of statin-induced VSMC apoptosis in the pathophysiology of atherosclerosis deserves further investigation.
In summary, HMG-CoA reductase inhibitors induce apoptosis of VSMCs in culture, probably through a reduction of isoprenoid concentration and the subsequent protein prenylation. A better understanding of the mechanisms involved in VSMC apoptosis and its pharmacological modulation may help to provide new strategies to modify the pathophysiology of atherosclerosis. 
